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Abstract
Background: Cerebrovascular disease is the third leading cause of death in the United States, and
about one-fourth of cerebrovascular deaths are attributed to ruptured intracranial aneurysms (IA).
Epidemiological evidence suggests that IAs cluster in families, and are therefore probably genetic.
Identification of individuals at risk for developing IAs by genetic tests will allow concentration of
diagnostic imaging on high-risk individuals. We used model-free linkage analysis based on allele
sharing with a two-stage design for a genome-wide scan to identify chromosomal regions that may
harbor IA loci.
Methods: We previously estimated sibling relative risk in the Finnish population at between 9 and
16, and proceeded with a genome-wide scan for loci predisposing to IA. In 85 Finnish families with
two or more affected members, 48 affected sibling pairs (ASPs) were available for our genetic
study. Power calculations indicated that 48 ASPs were adequate to identify chromosomal regions
likely to harbor predisposing genes and that a liberal stage I lod score threshold of 0.8 provided a
reasonable balance between detection of false positive regions and failure to detect real loci with
moderate effect.
Results: Seven chromosomal regions exceeded the stage I lod score threshold of 0.8 and five
exceeded 1.0. The most significant region, on chromosome 19q, had a maximum multipoint lod
score (MLS) of 2.6.
Conclusions: Our study provides evidence for the locations of genes predisposing to IA. Further
studies are necessary to elucidate the genes and their role in the pathophysiology of IA, and to
design genetic tests.
Published: 1 August 2002
BMC Medical Genetics 2002, 3:7
Received: 27 March 2002
Accepted: 1 August 2002
This article is available from: http://www.biomedcentral.com/1471-2350/3/7
© 2002 Olson et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted 
in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/7
Page 2 of 7
(page number not for citation purposes)
Background
In spite of advances in surgical and pharmacological treat-
ment, about half of the aneurysmal subarachnoid hemor-
rhage (SAH) patients die and many who survive need
rehabilitation to maintain independence, causing signifi-
cant economic losses to medical and social care. About
90% of SAH cases are caused by a ruptured IA [1]. Per-case
mortality for ruptured IAs is about 30 to 50% and morbid-
ity about 66% as opposed to about 2% mortality and 4%
morbidity for elective surgery of unruptured IAs in asymp-
tomatic low-risk patients [2,3]. Given the marked contrast
between the outcomes of elective versus emergency sur-
gery, the goal has to be identification and treatment of IAs
prior to rupture.
There is substantial debate regarding the cost-benefit ratio
of population screening [4–8]. Restricting screening to
those individuals at high risk both for developing IA and
for rupture would improve the cost-benefit ratio. Charac-
terization of environmental and genetic risk factors would
allow not only reduction of risk through behavior modifi-
cation, but also significantly improve detection. Addition-
ally, some environmental and genetic risk factors may be
amenable to pharmacological intervention. Simple tests
for genetic risk factors would permit the identification of
individuals at high risk for development and rupture of
aneurysms, consequently allowing diagnostic effort to be
concentrated on a smaller group that is at higher risk.
Currently, several risk factors have been identified includ-
ing cigarette smoking, arterial hypertension, gender, ag-
ing, atherosclerosis and heavy alcohol consumption [9–
12]. Initial indications of a genetic component were based
on collections of case reports that suggested that IAs are
associated with some rare simple Mendelian disorders,
e.g. autosomal dominant polycystic kidney disease, Ehlers
Danlos syndrome type IV and the Marfan syndrome [13].
More recent systematic prevalence estimates indicate ei-
ther absence of association or markedly reduced preva-
lence of IA among patients with rare simple Mendelian
disorders [14,15]. Also, genetic analyses of genes known
to cause some simple Mendelian disorders have proven
negative for collections of patients with IA [16,17]. The fa-
milial occurrence of IAs not associated with known simple
Mendelian disorders was first noted in 1942 [18] and,
since then, nearly one hundred case reports and review ar-
ticles have been published. Population-based studies of
SAH probands show that 7 to 10% have a family history
of IA, a higher percentage than previously appreciated
[1,19,20]. These familial IA (FIA) families have no signs of
any other simple Mendelian disorders predisposing to IA,
supporting the possibility that some or all IAs have a ge-
netic component, and that FIA is a genetic disease separate
and apart from previously defined diseases. The inherit-
ance patterns of FIA have not been determined, partly be-
cause IA is a late age-at-onset disease and partly because it
is likely to be a multifactorial disease for which simple
Mendelian models will not fit well [1,21–23].
Methods
Study subjects
Eighty-five families with at least two members with rup-
tured or unruptured IA and no family history of polycystic
kidney disease were ascertained from a sampling frame of
1150 consecutive patients treated between 1977 and 1990
for aneurysmal SAH by the Department of Neurosurgery
at the University Hospital of Kuopio, which serves a genet-
ically homogenous population of 870,000 in eastern Fin-
land [1]. Initially, family history was assessed by a short
questionnaire and all putative cases were confirmed from
medical and autopsy records. Due to the high mortality of
IA and lack of pre-rupture symptoms, surviving relatives
with known IA were rare. We therefore used magnetic res-
onance angiography to screen 264 siblings over the age of
30 of the IA probands [1]. Positive magnetic resonance
angiography findings were then confirmed using digital
subtraction angiography. Upper-abdominal ultrasonogra-
phy was performed on all screened individuals and con-
firmed that none of these individuals had evidence of
polycystic kidney disease. In this manner, we detected 30
siblings with asymptomatic IA, giving a total of 49 affect-
ed sib pairs from 25 sibships (22 extended families; fami-
lies 10, 21 and 29 had two sibships each; Figure 1 and
Table 1). One non-sib pair was detected in one of the sib-
ships in family 21 (see Statistical analyses below; Figure 1)
and eliminated from the analyses, leaving 48 ASPs for the
genome scan. The ASPs were comprised of 26 males and
34 females. Blood samples were obtained from affected
family members, unaffected siblings, and parents, where
possible. Due to the late age at onset, parents were availa-
ble in only a few of the families. All family records were
confirmed through registries kept by the Evangelical Lu-
theran Church of Finland.
The study protocol was reviewed and approved by the In-
stitutional Review Boards of both the University Hospital
of Kuopio and Wayne State University.
Study design
Whole-genome scans are labor-intensive and costly since
each individual in the study must be genotyped for all
markers. Reduction of the number of samples genotyped,
or the number of markers, or both, has been shown to be
efficient [24–28]. We used a two-stage design. In stage 1,
samples are genotyped at low density and subsequently at
higher density in stage 2, thereby reducing the overall
number of markers genotyped. Stage 1 data were analysed
using a liberal α   0.05 (lod = 0.8). Regions exceeding the
threshold were genotyped in stage 2.BMC Medical Genetics 2002, 3 http://www.biomedcentral.com/1471-2350/3/7
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Power was computed assuming a two-stage design, 49
ASPs, and a map density of 15 cM. For stage I alone, we
had at least 96% power to detect "significant linkage" (lod
score of 3.6) [29] to a locus with a locus-specific relative
risk to siblings of 8 and at least 90% power to detect "sug-
gestive linkage" to a locus with a locus-specific relative risk
of 4.
DNA isolation and pre-amplification
Blood was collected into EDTA-containing tubes. Genom-
ic DNA was isolated either by an automated procedure
(Genepure DNA extractor, Applied Biosystems, Inc., Fos-
ter City, CA) or manually (Puregene DNA isolation kit,
Gentra Systems, Inc., Minneapolis, MN). Genotyping was
performed using genomic DNA, either untreated or am-
plified linearly using primer-extension preamplification
[30,31]. Approximately 0.5 µg genomic DNA was used for
preamplification with an N15-primer [30,31]. The result-
ing preamplified DNA was then used as a template in
marker PCRs with specific primers.
Genotyping
Most of the initial genotyping was performed by the Na-
tional Heart Lung and Blood Institute Mammalian Geno-
typing Service at the Marshfield Research Foundation
using the 10 cM Weber version 8 screening set [32]. Prim-
er pairs for additional markers were obtained from Re-
search Genetics, Inc. (Huntsville, AL). For the additional
genotyping, PCRs were carried out with one of the primers
radioactively labeled. PCRs were set up using a laboratory
workstation (Biomek 1000; Beckman, Palo Alto, CA) and
performed in PEC 9600 thermal cyclers (Perkin Elmer Ce-
tus, Foster City, CA). The alleles were scored visually from
autoradiographs and entered into an Oracle database (Or-
acle Corp., Redwood Shores, CA). Population frequencies
for each marker were estimated from a sample of 20 to 24
unrelated Finnish subjects.
Figure 1
FIA Pedigrees. The genome scan was performed with the 48 of 49 affected sibling pairs from the 24 sibships since one of the
pairs in family 21 was determined to be a non-sib pair. GT indicates that DNA from the corresponding individual was geno-
typed. Symbols are defined in the figure: DSA denotes digital subtractive angiography; MRA denotes magnetic resonance angi-
ography.
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Statistical analyses
A Markov-process-based test of genetic relationship [33]
using all the marker data across the genome was used on
each nuclear family to confirm the sib-pair relationship;
one non-sib pair was detected in one of the sibships in
family 21 (Figure. 1) and eliminated from the analyses.
The results were consequently derived from 24 sibships
(Figure 1).
The genotype data were analyzed for genetic linkage with
both single-marker and multipoint model-free ASP lod
score analysis [34] using the computer program MAP-
MAKER/SIBS [35].
Results
Genome-wide linkage analysis
We performed stage I of a two-stage genome scan using
the 48 Finnish ASPs. Due to the genetic homogeneity of
the Finnish population [36–40] the probability of identi-
fying genetic risk factors in a complex disease such as FIA
may be substantially improved [37,38,40]. In the first
stage a 10 cM genome scan was performed using the We-
ber screening set 8 [32] and the data analyzed using both
two-point and multipoint ASP linkage analysis. Seven re-
gions on chromosomes 4, 6, 7p, 7q, 14, 19, and X, with
multipoint lod scores exceeding 0.8 (pointwise P-value 
0.05) were identified (Table 2). Two regions had MLSs ex-
ceeding 2.0 (2.58 on chromosome 19; 2.08 on chromo-
some X). Two-point lod scores exceeded 1.0 for two
adjacent markers in each of these regions, ruling out sub-
stantial genotyping error in one marker as the cause of the
high lod scores. Three additional regions with multipoint
lod scores exceeding 0.8 (chromosomes 4, 6, and 7q) also
had substantial two-point lod scores at more than one
marker. For two regions (7p and 14q), however, only one
marker had a high two-point lod score. In both cases, the
significant marker was either the first or the last marker
typed on the chromosome. Following conventional
guidelines, we considered an MLS of 3.6 or greater to be
"significant linkage" and an MLS of 2.2 to be "suggestive
linkage" [29].
In stage 2, we genotyped additional markers in the seven
regions identified in stage 1. Four additional markers
flanking D7S1819 on 7p and nine additional markers
flanking D14S1434 on 14q were typed and the resulting
maximum MLSs were 0.28 (7p) and 0.80 (14q), indicat-
ing that the previous linkage signals were likely due to the
increased statistical variability commonly seen in the
multipoint signal at the most extreme markers. We there-
fore eliminated regions 7p and 14q from further consider-
ation. Additional markers were typed in the two regions
on chromosome 19 and X with maximum MLSs exceed-
ing 2.0. A multipoint plot for the chromosome 19 is
shown in Figure 2; the maximum MLS was 2.58 at
D19S245 – D19S246. The maximum MLS for chromo-
some X decreased from 2.08 at DXS987 to 1.33 at
DXS1226, (about 10 cM centromeric from DXS987). The
MLS for the region on chromosome X decreased consider-
ably with the addition of several new markers and conse-
quent improvement in the accuracy of the multipoint
allele-sharing estimates, which were clearly overestimated
when only the initial scan markers were included in the
analysis. All the evidence for linkage in this region was
due to 8 brother-brother pairs; the 16 sister-sister pairs
and the 25 brother-sister pairs gave maximum MLSs close
to zero in this region.
Discussion
The relatively high prevalence of IAs and aneurysmal SAH
place the disease in the group of moderately common dis-
orders. Consequently, it shares some of the features that
make common disorders complex with respect to genetic
analysis. These include: low sibling relative risks due to
Table 1: Distribution of Affected Sibship Sizes
Affected Siblings Sibships Affected Pairs
21 8 1 8
35 1 5
41 6
51 1 0
Figure 2
Chromosome 19 multipoint lod score versus genetic dis-
tance (cM). Also indicated below the cM scale are the poly-
morphic markers.
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the high population prevalence; presence of multiple ge-
netic loci, each contributing a small portion of the sibling
relative risk; incomplete penetrance of genetic loci; envi-
ronmental risk factors; late age at onset; and phenocopies,
i.e. disease due to purely environmental factors. Addition-
al complexity for genetic analysis arises due to diagnostic
uncertainty. Several measures were taken to increase the
probability of success. We used robust, model-free, allele-
sharing genetic analyses to address the complexity, we
studied a relatively genetically homogenous population,
and we verified that all putative IAs were saccular
[1,20,41–43]. It is expected that a genetically homogene-
ous population, particularly one with a recent population
bottleneck [37,38], segregates for fewer disease loci there-
by allowing a smaller sample size to be informative. Addi-
tionally, our study design was cost-effective, two-stage
design with 48 ASPs. We are collecting an additional 150
ASPs for further study.
The most promising locus with a maximum MLS of 2.6
was on chromosome 19. The peak is located approximate-
ly in 19q12–13, a gene-rich region containing a number
of loci related to cerebrovascular, cardiovascular and
membrane physiology and pathobiology. These include
urokinase-type plasminogen activator receptor (PLAUR;
MIM 173391, see Online Mendelian Inheritance in Man
[http://www.ncbi.nlm.nih.gov/omim/]) [44], apolipo-
proteins E (MIM 107741), CII (MIM 207750) and CI
(MIM 107710), human brain-specific Na(+)-dependent
inorganic phosphate cotransporter (hBNPI, 19q13) [45],
cardiac troponin I (TnIc, 19q; MIM 191044) [46,47], cer-
ebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL, caused by
mutations in the Notch3 gene, 19q12; MIM 602275) [48],
isolated cardiac conduction disease (19q13.3; MIM
113900) [49], and progressive familial heart block type I
(PF-HBI, 19q13.2–13.3; MIM 113900) [50]. Mutations in
the P/Q-type Ca(2+)-channel alpha 1A-subunit gene on
19q12 cause familial hemiplegic migraine, episodic ataxia
type 2, and spinocerebellar ataxia type 6 (MIM 141500)
[51,52].
It is noteworthy that none of the regions in which we
found some evidence for linkage, either tentative or sug-
gestive, are similar to the regions detected in another re-
cent genome-wide scan for IA susceptibility genes [53].
Although our study found evidence for a region with ten-
tative linkage on chromosome 7q, the region identified in
this study is near the telomere and does not overlap with
the region of suggestive linkage near the centromere on 7q
identified in Onda et al. [53]. The populations that were
studied are distinct, Finns as compared to Japanese; how-
ever, both samples were small and it is therefore possible
that there may yet be some overlap in genetic predisposi-
tion.
Conclusions
We detected two regions of suggestive linkage, one on
chromosome 19 and the other on the X chromosome in a
sample of Finnish ASPs. Although we initially detected re-
gions of tentative linkage on chromosomes 4, 6, 7p, 7q
and 14, the regions on 7p and 14 were excluded upon ad-
ditional genotyping. None of the regions detected in this
study overlap with the regions detected in a sample of Jap-
anese ASPs [53].
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